From: Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
Target | Agent | Pharmaceutical Supplier | Type | Dual-specific | Delivery method | Clinicaltrials.gov Identifier | Phase | Status | Cancer | Single agent | Combination |
---|---|---|---|---|---|---|---|---|---|---|---|
A2AR | Ciforadenant (CPI-444) | Corvus | Antagonist | N/A | Orally | NCT02655822 | I | Completed | RCC, mCRPC | YES | Atezolizumab |
 |  |  |  |  |  | NCT04280328 | I | Completed | MM | N/A | Daratumumab |
 |  |  |  |  |  | NCT03337698 | I/II | Recruiting | NSCLC | N/A | Atezolizumab |
 | CS3005 | CStone Pharmaceuticals | Antagonist | N/A | Orally | NCT04233060 | I | Completed | Advanced solid tumors | YES | N/A |
 | Etrumadenant (AB928) | Arcus Biosciences | Antagonist | A2AR/ A2BR | Orally | NCT03629756 | I | Completed | Advanced malignancies | N/A | Zimberelimab |
 |  |  |  |  |  | NCT03719326 | I | Completed | TNBC, OC | N/A | PLD, and/or IPI-549, NP |
 |  |  |  |  |  | NCT03720678 | I | Completed | mGEC, mCRC | N/A | CT |
 |  |  |  |  |  | NCT03846310 | I | Active, not recruiting | non-squamous NSCLC | N/A | CT, and/or anti-PD1 antibody |
 |  |  |  |  |  | NCT04892875 | I | Not yet recruiting | Locally advanced head and neck cancers | N/A | RT, CT, and zimberelimab |
 |  |  |  |  |  | NCT03193190 | I/II | Active, not recruiting | mPDAC | N/A | Atezolizumab and CT |
 |  |  |  |  |  | NCT03555149 | I/II | Recruiting | mCRC | N/A | Atezolizumab and regorafenib |
 |  |  |  |  |  | NCT04381832 | I/II | Recruiting | mCRPC | N/A | Zimberelimab, and/or CT; or with AB680 and/or zimberelimab |
 |  |  |  |  |  | NCT04660812 | I/II | Recruiting | mCRC | N/A | Zimberelimab and/or CT, bevacizumab, and Regorafenib |
 |  |  |  |  |  | NCT03821246 | II | Recruiting | Localized PC prior to radical prostatectomy | N/A | Atezolizumab |
 |  |  |  |  |  | NCT04262856 | II | Recruiting | mNSCLC | N/A | Zimberelimab and domvanalimab |
 |  |  |  |  |  | NCT04791839 | II | Recruiting | previously ICI-treated NSCLC | N/A | Zimberelimab and domvanalimab |
 |  |  |  |  |  | NCT05024097 | II | Recruiting | Rectal cancer | N/A | RT, CT, and zimberelimab |
 |  |  |  |  |  | NCT05335941 | II | Not yet recruiting | Previously treated advanced or metastatic MTAP-deficient UC | N/A | Pemetrexed and zimberelimab |
 | Imaradenant (AZD4635) | AstraZeneca | Antagonist | N/A | Orally | NCT02740985 | I | Active, not recruiting | Advanced solid malignancies | YES | Durvalumab, or abiraterone acetate enzalutamide, or docetaxel; with durvalumab and oleclumab |
 |  |  |  |  |  | NCT03980821 | I | Completed | Advanced solid malignancies | YES | N/A |
 |  |  |  |  |  | NCT04089553 | II | Active, not recruiting | PC | N/A | Durvalumab or oleclumab |
 |  |  |  |  |  | NCT04495179 | II | Active, not recruiting | mCRPC | N/A | Durvalumab, ± cabazitaxel |
 | INCB106385 | Incyte | Antagonist | A2AR/ A2BR | Orally | NCT04580485 | I | Recruiting | Advanced solid tumors | YES | INCMGA00012 |
 | Inupadenant (EOS100850) | iTeos Therapeutics | Antagonist | N/A | Orally | NCT03873883 | I | Recruiting | Adult solid tumors | YES | Pembrolizumab or CT |
 |  |  |  |  |  | NCT05117177 | I | Recruiting | Adult solid tumors | YES | N/A |
 |  |  |  |  |  | NCT05060432 | I/II | Recruiting | Advanced solid tumors | N/A | EOS-448 |
 | PBF-999 | Palo Biopharma | Antagonist | A2AR/ PDE-10 | Orally | NCT03786484 | I | Recruiting | Advanced solid tumors | YES | N/A |
 | Preladenant (MK-3814) | Merck | Antagonist | N/A | Orally | NCT03099161 | I | Terminateda | Advanced solid tumors | YES | Pembrolizumab |
 | Taminadenant (NIR178/PBF-509) | Palo Biopharma (Novartis) | Antagonist | N/A | Orally | NCT02403193 | I | Recruiting | Advanced solid tumors | N/A | KAZ954 |
 |  |  |  |  |  | NCT03742349 | I | Recruiting | Advanced/relapsed RCC and other malignancies with HIF stablizing mutations | N/A | PDR001 and DFF332 |
 |  |  |  |  |  | NCT04237649 | I | Recruiting | Advanced solid tumors | N/A | KAZ954 |
 |  |  |  |  |  | NCT04895748 | I | Recruiting | Advanced/relapsed RCC and other malignancies with HIF stablizing mutations | N/A | PDR001 and DFF332 |
 |  |  |  |  |  | NCT03207867 | II | Active, not recruiting | Solid tumors and NHL | N/A | PDR001 |
A2BR | PBF-1129 | Palo Biopharma | Antagonist | N/A | Orally | NCT03274479 | I | Recruiting | Locally advanced/metastatic NSCLC | YES | N/A |
 |  |  |  |  |  | NCT05234307 | I | Not yet recruiting | Recurrent/metastatic NSCLC | N/A | Nivolumab |
 | TT-4 | Tarus Therapeutics | Antagonist | N/A | Orally | NCT04976660 | I/II | Not yet recruiting | Advanced selected solid tumors | YES | N/A |
 | TT-702 | Teon Therapeutics | Antagonist | N/A | Orally | NCT05272709 | I/II | Recruiting | Advanced solid tumors | YES | N/A |
CD39 | ES002023 | Elpiscience Biopharma | Antibody | N/A | I.V | NCT05075564 | I | Recruiting | Locally advanced or metastatic solid tumors | YES | N/A |
 | IPH5301 | Innate Pharma | Antibody | N/A | I.V | NCT04261075 | I | Active, not recruiting | Advanced solid tumors | YES | Durvalumab, ± oleclumab |
 |  |  |  |  |  | NCT05143970 | I | Recruiting | Advanced solid tumors | YES | CT and trastuzumab |
 | PUR001 | Purinomia Biotech | Antibody | N/A | I.V | NCT05234853 | I | Not yet recruiting | Advanced solid tumors | YES | N/A |
 | SRF617 | Surface Oncology | Antibody | N/A | I.V | NCT04336098 | I | Recruiting | Adult solid tumors | YES | CT or pembrolizumab, or both therapies |
 |  |  |  |  |  | NCT05177770 | II | Recruiting | mCRPC, PC | N/A | Etrumadenant and zimberelimab |
 | TTX-030 | Trishula Therapeutics (AbbVie) | Antibody | N/A | I.V | NCT03884556 | I | Active, not recruiting | Advanced cancers | YES | CT or pembrolizumab |
 |  |  |  |  |  | NCT04306900 | I | Recruiting | Advanced cancers | N/A | CT, or budigalimab, or pmebrolizumab, or budigalimab and CT |
CD73 | AK119 | Akesobio | Antibody | N/A | I.V | NCT04572152 | I | Recruiting | Advanced solid tumors | YES | AK104 |
 |  |  |  |  |  | NCT05173792 | I | Recruiting | Advanced solid tumors | YES | N/A |
 | ATG-037 | Antengene | Antagonist | N/A | Orally | NCT05205109 | I | Not yet recruiting | Locally advanced or metastatic solid tumors | YES | Pembrolizumab |
 | BMS-986179 | BMS | Antibody | N/A | I.V | NCT02754141 | I/II | Active, not recruiting | Malignant solid tumor | YES | Nivolumab or rHuPH20 |
 | GS-1423 | Gilead Sciences | Antibody | CD73/ TGFβRII | I.V | NCT03954704 | I | Terminatedb | Advanced solid tumors | YES | CT |
 | HLX23 | Henlius Biotech | Antibody | N/A | I.V | NCT04797468 | I | Not yet recruiting | Advanced solid tumors | YES | N/A |
 | IBI325 | Innovent Biologics | Antibody | N/A | I.V | NCT05119998 | I | Recruiting | Advanced solid tumors | YES | Sintilimab |
 |  |  |  |  |  | NCT05246995 | I | Not yet recruiting | Advanced solid tumors | N/A | Sintilimab |
 | INCA00186 | Incyte | Antibody | N/A | I.V | NCT04989387 | I | Recruiting | Advanced solid tumors | N/A | INCB106385, ± retifanlimab |
 | JAB-BX102 | Jacobio | Antibody | N/A | I.V | NCT05174585 | I/II | Not yet recruiting | Advanced solid tumors | YES | Pembrolizumab |
 | LY3475070 | Eli Lilly | Antagonist | N/A | Orally | NCT04148937 | I | Active, not recruiting | Advanced cancers | YES | Pembrolizumab |
 | Mupadolimab (CPI-006) | Corvus | Antibody | N/A | I.V | NCT03454451 | I | Recruiting | Advanced cancers | YES | Ciforadenant or pembrolizumab |
 | NZV930(SRF373) | Surface Oncology | Antibody | N/A | I.V | NCT03549000 | I | Recruiting | Advanced malignancies | YES | PDR001 or NIR178, or both agents |
 |  |  |  |  |  | NCT04237649 | I | Recruiting | Advanced solid tumors | N/A | KAZ954 |
 | Oleclumab (MEDI9447) | Medimmune (AstraZeneca) | Antibody | N/A | I.V | NCT02503774 | I | Active, not recruiting | Select advanced solid tumors | YES | Durvalumab |
 |  |  |  |  |  | NCT03736473 | I | Completed | Advanced solid malignancies | YES | N/A |
 |  |  |  |  |  | NCT03773666 | I | Active, not recruiting | Muscle-invasive bladder cancer | N/A | Durvalumab |
 |  |  |  |  |  | NCT03819465 | I | Not yet recruiting | Previously untreated NSCLC | N/A | Durvalumab, ± CT |
 |  |  |  |  |  | NCT03381274 | I/II | Active, not recruiting | NSCLC | N/A | Osimertinib or AZD4635 |
 |  |  |  |  |  | NCT03611556 | I/II | Active, not recruiting | metastatic pancreatic cancer | N/A | CT, ± durvalumab |
 |  |  |  |  |  | NCT03616886 | I/II | Active, not recruiting | Previously untreated locally recurrent inoperable or metastatic TNBC | N/A | Durvalumab and CT |
 |  |  |  |  |  | NCT03742102 | I/II | Recruiting | mTNBC | N/A | Durvalumab and CT |
 |  |  |  |  |  | NCT04068610 | I/II | Active, not recruiting | MSS-CRC | N/A | Durvalumab, bevacizumab, and CT |
 |  |  |  |  |  | NCT03267589 | II | Completed | Relapsed OC | N/A | Durvalumab, tremililumab, and MEDI0562 |
 |  |  |  |  |  | NCT03334617 | II | Recruiting | NSCLC | N/A | Durvalumab |
 |  |  |  |  |  | NCT03794544 | II | Completed | Resectable NSCLC | N/A | Durvalumab |
 |  |  |  |  |  | NCT03822351 | II | Active, not recruiting | NSCLC | N/A | Durvalumab |
 |  |  |  |  |  | NCT03833440 | II | Recruiting | ICI-resistant NSCLC | N/A | Durvalumab |
 |  |  |  |  |  | NCT03875573 | II | Recruiting | Luminal B breast cancer | N/A | SBRT and durvalumab |
 |  |  |  |  |  | NCT04145193 | II | Withdrawnc | MSS-CRC | N/A | Durvalumab and CT |
 |  |  |  |  |  | NCT04262375 | II | Withdrawnd | NSCLC, RCC | N/A | Durvalumab |
 |  |  |  |  |  | NCT04262388 | II | Withdrawne | PDSC, NSCLC, HNSC | N/A | Durvalumab |
 |  |  |  |  |  | NCT04668300 | II | Recruiting | Recurrent, refractory, or metastatic sarcoma | N/A | Durvalumab |
 |  |  |  |  |  | NCT04940286 | II | Recruiting | Resectable/borderline resectable primary pancreatic cancer | N/A | Durvalumab and CT |
 |  |  |  |  |  | NCT05061550 | II | Not yet recruiting | Resectable NSCLC | N/A | Durvalumab |
 |  |  |  |  |  | NCT05221840 | III | Recruiting | Stage III unresectable NSCLC | N/A | Durvalumab |
 | ORIC-533 | ORIC Pharmaceuticals | Antagonist |  | Orally | NCT05227144 | I | Recruiting | Relapsed or refractory MM | YES | N/A |
 | Quemliclustat (AB680) | Arcus Biosciences | Antagonist |  | I.V | NCT04104672 | I | Recruiting | Gastrointestinal malignancies | N/A | CT or CT and zimberelimab |
 |  |  |  |  |  | NCT04381832 | I/II | Recruiting | mCRPC | N/A | Etrumadenant and/or zimberelimab |
 |  |  |  |  |  | NCT04660812 | I/II | Recruiting | mCRPC | N/A | AB928 and zimberelimab |
 | Sym024 | Symphogen | Antibody |  | I.V | NCT04672434 | I | Recruiting | Advanced solid tumors | YES | Sym021 |
 | Uliledlimab (TJ004309) | TRACON Pharmaceuticals | Antibody |  | I.V | NCT03835949 | I | Active, not recruiting | Advanced or metastatic cancer | N/A | Atezolizumab |
 |  |  |  |  |  | NCT04869501 | N/A | No longer available | Advanced or metastatic cancer | N/A | Atezolizumab |
 |  |  |  |  |  | NCT04322006 | I/II | Recruiting | Advanced solid tumors | YES | Anti-PD1 antibody |
 |  |  |  |  |  | NCT05001347 | II | Recruiting | OC and selected solid tumors | YES | N/A |